论文部分内容阅读
目的探讨吡柔比星(pirarubicin,THP)、羟基喜树碱(hydroxycamptothecin,HCPT)、丝裂霉素(mitomycin,MMC)三种不同药物膀胱灌注化疗对预防膀胱癌保留膀胱术后复发的安全性评估。方法将162例晋东地区膀胱癌保留膀胱术后膀胱灌注的膀胱癌患者随机分为三组,Ⅰ组采用THP方案(76例),Ⅱ组采用HCTP方案(62例),Ⅲ组采用MMC方案(24例)。分别于术后1~2周开始规律膀胱灌注。比较三组复发率。结果所有患者均随访2年以上。Ⅰ组复发率为13.5%,Ⅱ组复发率14.8%,Ⅲ组复发率19.6%。Ⅰ、Ⅱ组与Ⅲ组比较差异有显著性(P<0.05)。结论THP、HCTP膀胱灌注对膀胱癌保留膀胱术后防止复发疗效满意,副作用轻,耐受性好且安全。
Objective To investigate the safety of intravesical instillation chemotherapy with pirarubicin (THP), hydroxycamptothecin (HCPT) and mitomycin (MMC) in the prevention of bladder cancer recurrence after bladder irrigation Evaluation. Methods A total of 162 cases of bladder cancer with vesical bladder cancer after bladder surgery in the eastern part of the eastern part of China were randomly divided into three groups: group Ⅰ (76 cases), group Ⅱ (62 cases), group Ⅲ (group MMC) (24 cases). Regular bladder perfusion was started 1 to 2 weeks after surgery. Compare the recurrence rate of three groups. Results All patients were followed up for more than 2 years. The recurrence rate was 13.5% in group Ⅰ, 14.8% in group Ⅱ, and 19.6% in group Ⅲ. There was a significant difference between group Ⅰ, Ⅱ and group Ⅲ (P <0.05). Conclusion THP and HCTP were effective in preventing recurrence of vesicoureteral bladder after bladder irrigation, with mild side effects and good tolerability and safety.